MedTrace Logo

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

NCT04800081 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2021-03-16

No results posted yet for this study

Summary

To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to different factors and the protection of target organs.To provide reference for the clinical treatment of perimenopausal hypertension patients with shakubactrivalsartan.

1. To evaluate the effects of Sacubitril/Valsartan on urinary microalbumin and pulse wave velocity in perimenopausal hypertension patients.
2. To evaluate the clinical application of Sacubitril/Valsartan in the treatment of perimenopausal hypertension, so as to improve the blood pressure management ability and control rate of patients with such hypertension.

Conditions

Interventions

DRUG

Sacubitril/Valsartan

Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.

DRUG

Valsartan

Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.

Sponsors & Collaborators

  • LanZhou University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2021-06-09
Completion
2021-07-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800081 on ClinicalTrials.gov